May 5, 2025 03:59 PM EDT
R&D

PTC's Hunt­ing­ton’s study suc­ceeds, but ac­cel­er­at­ed ap­proval un­cer­tain

Lei Lei Wu

News Reporter

PTC Ther­a­peu­tics an­nounced Mon­day that its splic­ing drug for Hunt­ing­ton’s dis­ease met the pri­ma­ry end­point of a Phase 2 study, but …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

Ear­ly bits of in vi­vo CAR-T hu­man da­ta emerge from biotech tri­als in Chi­na

Re­cur­sion cuts near­ly half of its pipeline, in­clud­ing its most ad­vanced pro­gram

J&J's eye dis­ease gene ther­a­py bo­ta-vec fails in Phase 3 tri­al

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times